• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Black Diamond Therapeutics Inc (NQ: BDTX )

    2.540 +0.110 (+4.53%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 598,961
    Open 2.450
    Bid (Size) 2.400 (5)
    Ask (Size) 2.550 (1)
    Prev. Close 2.430
    Today's Range 2.400 - 2.615
    52wk Range 2.155 - 7.660
    Shares Outstanding 36,213,654
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire

    Performance

    YTD
    -12.71%
    -12.71%
    1 Month
    -16.99%
    -16.99%
    3 Month
    -60.68%
    -60.68%
    6 Month
    -48.06%
    -48.06%
    1 Year
    +12.39%
    +12.39%

    More News

    Read More
    Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Looking Into Black Diamond Therapeutic's Recent Short Interest
    Via Benzinga
    Black Diamond Therapeutic: Q4 Earnings Insights
    Via Benzinga
    Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements
    Via AB Newswire
    Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
    Via Benzinga
    Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
    From Gyre Therapeutics, Inc.
    Via GlobeNewswire
    BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024
    Via InvestorPlace
    Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024
    Via InvestorPlace
    Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Black Diamond Therapeutics Announces Changes to Board of Directors
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.